** Shares of ASX-listed Mesoblast MSB.AX rise 2.88% to A$2.14, set for third session of consecutive gains — if trends hold
** Stock among the biggest percentage gainers in the ASX200 index .AXJO
** Biotech releases pricing information for its product Ryoncil, used to treat a serious condition called graft-versus-host disease, which can happen after a person gets a blood cell transplant
** Treatment centres can now order kits tailored to the appropriate dosage for each patient, with pricing applied uniformly, regardless of patient weight — MSB
** Pricing details for Ryoncil are now available in all four major drug pricing compendia in the United States
** Says that this follows approval and publication by the U.S. Food and Drug Administration of the revised Ryoncil label, which includes revisions to the product prescribing information
** Stock down 31.3% YTD including current session
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.